Seppelt U, Bertermann H, Saerbeck C
Urologe A. 1986 Sep;25(5):298-301.
Thirteen patients with untreated prostate cancer were treated initially with subcutaneous 0.5 mg D-Trp6-LH-RH daily for the first week, 0.1 mg daily for the next three weeks and thereafter with intramuscular depot preparations of 3.2 mg every three weeks. Serum testosterone was suppressed to castration levels. Serum LH, FSH and prolactin were reduced, serum cortisol did not change. 10/13 patients showed remissions, as shown by transrectal prostate volumetry, cytological regression grading, serum phosphatases and clinical status. 3/13 tumors showing progression were undifferentiated and androgen-resistant. The investigated compound seems to be effective in selecting androgen sensitive tumors and may be a possible alternative to orchiectomy.
13例未经治疗的前列腺癌患者，第一周每天皮下注射0.5毫克D-色氨酸6-促黄体生成素释放激素，接下来三周每天注射0.1毫克，此后每三周肌肉注射3.2毫克长效制剂。血清睾酮被抑制至去势水平。血清促黄体生成素、促卵泡生成素和催乳素降低，血清皮质醇无变化。13例患者中有10例出现缓解，经直肠前列腺体积测量、细胞学消退分级、血清磷酸酶及临床状况证实。13例中有3例肿瘤进展，为未分化且雄激素抵抗型。所研究的化合物似乎在选择雄激素敏感肿瘤方面有效，可能是睾丸切除术的一种替代选择。
